Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7413797 | 0.78 | IDO1 (0.34) | DPP4 | |
| SCHEMBL2095477 | 0.77 | TAAR1 (0.36) | HTR2ATAAR1DPP4TSHRHRH1 | |
| SCHEMBL2095479 | 0.77 | TAAR1 (0.36) | HTR2ATAAR1DPP4TSHRHRH1 | |
| SCHEMBL6946458 | 0.77 | LMNA (0.41) | HTR2ATAAR1TSHRHRH1TRPA1 | |
| SCHEMBL7427771 | 0.77 | TSHR (0.39) | HTR2ATAAR1DPP4TSHRHRH1 | |
| SCHEMBL8522965 | 0.77 | DPP4 (0.45) | HTR2ATAAR1DPP4TSHRHRH1 | |
| SCHEMBL9317922 | 0.74 | CYP1A2 (0.42) | HTR2ATAAR1TSHRHRH1TRPA1 | |
| SCHEMBL9317926 | 0.74 | CYP1A2 (0.42) | HTR2ATAAR1TSHRHRH1TRPA1 | |
| SCHEMBL10361924 | 0.74 | ALDH1A1 (0.44) | TSHRALDH1A1 | |
| SCHEMBL2387572 | 0.69 | DPP4 (0.38) | HTR2ATAAR1DPP4TSHRHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488755-B2 | Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid | PRESTWICK PHARMACEUTICALS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | ORAPHARMA, INC. | 2005-11-24 | — | — | US | disclosed |
| US-5334720-A | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties | FISONS CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | GLRA3, GLRA1, GLRA2 | HTR2A 70/4885TAAR1 237/4885DPP4 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.